The diversity of mutations and clinical outcomes for ELANE-associated neutropenia

Purpose of reviewMutations in the gene for neutrophil elastase, ELANE, cause cyclic neutropenia (CyN) and severe congenital neutropenia (SCN). This study summarized data from the Severe Chronic Neutropenia International Registry (SCNIR) on genotype–phenotype relationships of ELANE mutations to important clinical outcomes. We also summarize findings for ELANE mutations not observed in SCNIR patients. Recent findingsThere were 307 SCNIR patients with 104 distinctive ELANE mutations who were followed longitudinally for up to 27 years. The ELANE mutations were diverse; there were 65 single amino acid substitutions; 61 of these mutations (94%) were ‘probably’ or ‘possibly damaging’ by PolyPhen-2 analysis, and one of the ‘benign’ mutations was associated with two cases of acute myeloid leukemia (AML). All frame-shift mutations (19/19) were associated with the SCN. The pattern of mutations in the SCN versus CyN was significantly different (P < 10–4), but some mutations were observed in both groups (overlapping mutations). The cumulative incidence of severe adverse events, that is, myelodysplasia, AML, stem cell transplantation, or deaths was significantly greater for patients with SCN versus those with CyN or overlapping mutations. Specific mutations (i.e. G214R or C151Y) had a high risk for evolution to AML. SummarySequencing is useful for predicting outcomes of ELANE-associated neutropenia.

[1]  Xiaodong Zhao,et al.  Clinical Characteristics of Severe Congenital Neutropenia Caused by Novel ELANE Gene Mutations , 2015, The Pediatric infectious disease journal.

[2]  S. Corey,et al.  PHAGOCYTES , GRANULOCYTES , AND MYELOPOIESIS Neutropenia-associated ELANE mutations disrupting translation initiation produce novel neutrophil elastase isoforms , 2014 .

[3]  N. Borregaard.  Severe congenital neutropenia: new lane for ELANE. , 2014, Blood.

[4]  D. Steinemann,et al.  Cooperativity of RUNX1 and CSF3R mutations in severe congenital neutropenia: a unique pathway in myeloid leukemogenesis. , 2013, Blood.

[5]  H. Grimes,et al.  Myelopoiesis From Induced Pluripotent Stem Cells Reveals The Role Of Elastase Activity In The Pathogenesis Of Severe Congenital Neutropenia , 2013 .

[6]  M. Ballmaier,et al.  The Spectrum of ELANE Mutations and their Implications in Severe Congenital and Cyclic Neutropenia , 2013, Human mutation.

[7]  S. Corey,et al.  ELANE mutations in cyclic and severe congenital neutropenia: genetics and pathophysiology. , 2013, Hematology/oncology clinics of North America.

[8]  K. Welte,et al.  Mutations in the TNFRSF1A, CEBPE and ELANE genes in a Congenital Cyclic Neutropenia Patient: A New Syndrome? , 2012 .

[9]  D. Link,et al.  Activation of the unfolded protein response is associated with impaired granulopoiesis in transgenic mice expressing mutant Elane. , 2011, Blood.

[10]  P. Newburger,et al.  Cyclic neutropenia and severe congenital neutropenia in patients with a shared ELANE mutation and paternal haplotype: Evidence for phenotype determination by modifying genes , 2010, Pediatric blood & cancer.

[11]  Philip S Rosenberg,et al.  Stable long‐term risk of leukaemia in patients with severe congenital neutropenia maintained on G‐CSF therapy , 2010, British journal of haematology.

[12]  R. Beekman,et al.  G-CSF and its receptor in myeloid malignancy. , 2010, Blood.

[13]  P. Bork,et al.  A method and server for predicting damaging missense mutations , 2010, Nature Methods.

[14]  L. Blancas Galicia,et al.  [Severe congenital neutropenia]. , 2010, Revista alergia Mexico.

[15]  D. Link,et al.  Prevalence of mutations in ELANE, GFI1, HAX1, SBDS, WAS and G6PC3 in patients with severe congenital neutropenia , 2009, British journal of haematology.

[16]  B. Korkmaz,et al.  Neutrophil elastase, proteinase 3 and cathepsin G: physicochemical properties, activity and physiopathological functions. , 2008, Biochimie.

[17]  R. Wilson,et al.  Distinct patterns of mutations occurring in de novo AML versus AML arising in the setting of severe congenital neutropenia. , 2007, Blood.

[18]  Jun Xia,et al.  Mutations of the ELA2 gene found in patients with severe congenital neutropenia induce the unfolded protein response and cellular apoptosis. , 2006, Blood.

[19]  Mauno Vihinen,et al.  Bioinformatic analysis of protein structure–function relationships: case study of leukocyte elastase (ELA2) missense mutations , 2006, Human mutation.

[20]  Holger Heyn,et al.  Mutations in neutrophil elastase causing congenital neutropenia lead to cytoplasmic protein accumulation and induction of the unfolded protein response. , 2006, Blood.

[21]  D. Dale,et al.  Strong evidence for autosomal dominant inheritance of severe congenital neutropenia associated with ELA2 mutations. , 2006, The Journal of pediatrics.

[22]  Fernando Rodrigues-Lima,et al.  Mutations in the ELA2 gene correlate with more severe expression of neutropenia: a study of 81 patients from the French Neutropenia Register. , 2004, Blood.

[23]  M. Freedman,et al.  Severe chronic neutropenia: Treatment and follow‐up of patients in the Severe Chronic Neutropenia International Registry , 2003, American journal of hematology.

[24]  D C Linch,et al.  Mutations in the ELA2 gene encoding neutrophil elastase are present in most patients with sporadic severe congenital neutropenia but only in some patients with the familial form of the disease. , 2001, Blood.

[25]  C Bos,et al.  Mutations in the gene encoding neutrophil elastase in congenital and cyclic neutropenia. , 2000, Blood.

[26]  Philip H. Ramsey.  Nonparametric Statistical Methods , 1974, Technometrics.

[27]  A Ohara,et al.  [Cyclic neutropenia]. , 2000, Ryoikibetsu shokogun shirizu.

[28]  David C. Dale,et al.  Mutations in ELA2, encoding neutrophil elastase, define a 21-day biological clock in cyclic haematopoiesis , 1999, Nature Genetics.

[29]  A. Agresti.  [A Survey of Exact Inference for Contingency Tables]: Rejoinder , 1992 .

[30]  J. Falloon,et al.  Neutrophil granules in health and disease. , 1986, The Journal of allergy and clinical immunology.

[31]  F. Liddell,et al.  Simple exact analysis of the standardised mortality ratio. , 1984, Journal of epidemiology and community health.

[32]  F. Wilcoxon.  Individual Comparisons by Ranking Methods , 1945 .